

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hospital Corporation of China Limited

弘和仁愛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3869)

**CHANGE OF DIRECTORS;
CHANGE IN MEMBER OF THE REMUNERATION COMMITTEE,
AUDIT COMMITTEE AND NOMINATION COMMITTEE;
AND
RE-COMPLIANCE WITH RULES 3.10(1), 3.10A, 3.21 AND
3.27A OF THE LISTING RULES**

RESIGNATION OF EXECUTIVE DIRECTOR AND MEMBER OF THE REMUNERATION COMMITTEE

The board (“**Board**”) of directors (“**Directors**”, and each individually a “**Director**”) of Hospital Corporation of China Limited (the “**Company**”, together with its subsidiaries collectively, the “**Group**”) hereby announces that Mr. Pu Chengchuan (“**Mr. Pu**”) has tendered his resignation as an executive Director and a member of the remuneration committee of the Board (“**Remuneration Committee**”) with effect from 22 September 2026 due to his other work commitments.

Mr. Pu has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its gratitude to Mr. Pu for his contribution to the Company during his tenure of office.

REDESIGNATION OF DIRECTOR

The Board announces that with effect from 22 September 2026, Mr. Cao Yonggang (“**Mr. Cao**”) has been redesignated from a non-executive Director to an executive Director. Mr. Cao has been the chairman of the Board and a non-executive Director since 22 June 2026.

Mr. Cao, aged 54, joined Hony Capital (a series of private equity investment funds, together with their respective management companies/general partners, “**Hony Capital**”) in 2004 and currently serves as group chief executive officer of Hony Capital. He plays a critical role in the firm’s investment decisions and daily operations from the perspectives of corporate development, risk management and governance. He oversees the firm’s full spectrum of investment strategies, including PE, public funds, hedge funds, RE funds and VC funds, with total assets under management exceeding RMB120 billion.

With extensive legal background and professional experience, Mr. Cao has participated in many important investments of Hony Group, including projects such as CSPC Pharmaceutical Group, Simcere Pharmaceutical, Linyang Solar Energy and Boloni Home. He also previously served as chairman of the supervisory committee of Zoomlion Heavy Industry Science & Technology Co., Ltd. (a company listed on the Shenzhen Stock Exchange with stock code: 000157 and the Stock Exchange with stock code: 01157) and a member of the supervisory committee of Happy Go (now Mango Super Media Co., Ltd., a company listed on the Shenzhen Stock Exchange with stock code: 300413). Since 22 May 2026, Mr. Cao has been appointed as a non-executive director of YNBY International Limited (a company listed on the Stock Exchange with stock code: 00030). Mr. Cao holds an LL.B. in Civil and Commercial Law from Nankai University, an LL.M. in International Law from Peking University, an LL.M. in International Law and WTO Law from Erasmus University Rotterdam, and an EMBA degree from China Europe International Business School (CEIBS).

The term of office of Mr. Cao shall be three years commencing on 22 September 2026, and is subject to retirement by rotation and re-election in accordance with the Articles of Association. The Company will enter into a service contract with Mr. Cao. Mr. Cao will not receive any emoluments pursuant to the service contract.

As at the date of this announcement, Mr. Cao is interested in 255 shares of Exponential Fortune Group Limited, an associated corporation of the Company, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

As at the date of this announcement, so far as the Directors are aware and save as disclosed above, Mr. Cao (i) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas during the past three years; and (ii) does not hold any other position in the Group.

APPOINTMENT OF DIRECTORS

The Board further announces that pursuant to the articles of association (“**Articles of Association**”) of the Company and upon recommendation made by the nomination committee of the Board (“**Nomination Committee**”), (i) Dr. Sun Changyu (孫昌宇) (“**Dr. Sun**”) has been appointed as a non-executive Director; and (ii) Ms. Cheng Jessica (鄭宇凌) (formerly known as 鄭靜筠) (“**Ms. Cheng**”) has been appointed as an independent non-executive Director of the Company with effect from 22 September 2026.

The biographical details of Dr. Sun and Ms. Cheng and other information required to be disclosed under Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange are set out below:

Dr. Sun, aged 56, holds a doctoral degree. He joined Hony Capital in 2011 and currently serves as a managing director of Hony Capital and the general manager of its Investment Management Department. He is responsible for strategic resource allocation and overall management across the various investment business segments of Hony Capital.

Dr. Sun served as a non-executive director of COFCO Capital Holdings Co., Ltd. (中糧資本控股股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002423.SZ), from March 2019 to November 2025. Prior to joining Hony Capital, he served as an executive assistant to general manager of the Information Technology Department of the Hainan Branch of China Construction Bank, during which he was seconded to serve as a vice president of the Lingshui County Sub-branch of China Construction Bank. He also served as the general manager of Beijing Tongjian Anti-counterfeiting Technology Co., Ltd. (北京通鑒防偽科技有限公司), and the head of each of the RMB Investment Management Division and the Project Management Division of the Investment Management Department of China Life Insurance Company Limited.

The term of office of Dr. Sun shall be three years commencing on 22 September 2026, and is subject to retirement by rotation and re-election in accordance with the Articles of Association. The Company will enter into a service contract with Dr. Sun. Dr. Sun will not receive any emoluments pursuant to the service contract.

As at the date of this announcement, so far as the Directors are aware and save as disclosed above, Dr. Sun (i) has not held any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas during the past three years; and (ii) does not hold any other position in the Group.

Ms. Cheng, aged 46, has over 18 years of experience in the healthcare industry. Since November 2025, Ms. Cheng has served as the founding director and chief operating officer of the Minimally Invasive Neurosurgery Training Academy (a Hong Kong non-profit organisation providing continuing medical education); and since November 2020, she has served as the sole director of Celestial Wealth Limited, a company principally engaged in the provision of medical consultancy services.

Ms. Cheng was an independent non-executive director of Clarity Medical Group Holding Limited (a company providing private ophthalmic services, the shares of which are listed on the Stock Exchange, stock code: 1406) from 29 May 2024 to 6 January 2026. Prior to that, Ms. Cheng held various positions in a number of public and private healthcare institutions, including serving as the president of Genesis GBA Limited (a subsidiary of Genesis Medical Technology Group, an international medical device company) from July 2021 to December 2023; and as a consultant to Genesis Medical Technology Group from January 2024 to December 2025; the chief operating officer of the Greater Bay Area and Strategic Investment Department of WeDoctor (Hong Kong) Limited from November 2018 to December 2020; and the chief representative for Greater China and Southeast Asia of Telstra Health (a business division of Telstra Corporation Limited focusing on the provision of digital healthcare solutions) from September 2014 to June 2016. Telstra Corporation Limited is an Australian telecommunications company, the shares of which are listed on the Australian Securities Exchange, the New Zealand Stock Exchange and NASDAQ (ASX: TLS; NZX: TLS; NASDAQ: TLSYY). From October 2009 to March 2014, Ms. Cheng served as the manager of the Chairman and Chief Executive's Office of the Hong Kong Hospital Authority; and from May 2002 to March 2007, she held various positions at The Hong Kong College of Family Physicians, including executive officer, executive manager (education) and executive manager.

Ms. Cheng obtained a Bachelor of Business Administration degree from the University of Kent (formerly known as the University of Kent at Canterbury) in 2001; a Master of Science degree in Training and Human Resource Management from the University of Leicester in 2010; and a Certificate in the Roles and Functions of Independent Non-executive Directors from The Hong Kong Institute of Directors in 2025.

Ms. Cheng has served as a member of the 13th Guangdong Provincial Committee of the Chinese People's Political Consultative Conference since January 2023; the Deputy Director of the Medicine and Health Committee of the Council for the Promotion of Guangdong-Hong Kong-Macao Cooperation since March 2023; a member of the Hospital Governing Committee of the Pamela Youde Nethersole Eastern Hospital in Hong Kong since April 2023; a council member of the Guangdong International Culture Exchange Centre since August 2024; a member of the Programme and Development Committee of the Culture, Sports and Tourism Bureau of Hong Kong since November 2024; a member of the Lung Tong Area Committee in the Kowloon City District of Hong Kong since January 2023; and the Honorary Secretary of the Little Life Warrior Society (a Hong Kong non-profit charitable organisation providing support to children with cancer and their families) since September 2017. In March 2023, Ms. Cheng was recognised as an Outstanding Community Service Individual by the Home and Youth Affairs Bureau of Hong Kong.

Ms. Cheng has entered into an engagement letter with the Company regarding her appointment as an independent non-executive Director of the Company with an initial term of three years, during which she shall be subject to retirement and re-election in accordance with the Articles of Association. Accordingly, Ms. Cheng will only hold office until the first general meeting of the Company after her appointment and shall then be eligible for re-election at that general meeting, and thereafter subject to retirement by rotation at least once every three years at the annual general meeting in accordance with the memorandum and articles of association of the Company. Ms. Cheng is entitled to remuneration of RMB300,000 per annum which is determined with reference to her qualifications and experience, her duties and responsibilities and the Company's remuneration policy and prevailing market conditions.

As at the date of this announcement, so far as the Directors are aware and save as disclosed above, Ms. Cheng (i) has not held any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; and (ii) does not hold any other position in the Group.

Ms. Cheng has confirmed (i) her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules; (ii) that she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected persons (as defined under the Listing Rules) of the Company; and (iii) that there are no other factors that may affect her independence at the time of her appointment. The Board has assessed her independence and considers that she meets the independence requirements under Rule 3.13 of the Listing Rules.

Save as disclosed above, each of Mr. Cao, Dr. Sun and Ms. Cheng (i) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company, (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong), and (iii) does not hold other major appointments and professional qualifications.

Save as disclosed above, there are no other matters that need to be disclosed pursuant to the requirements under Rule 13.51(2) of the Listing Rules, nor is there any other matter relating to the appointments of Mr. Cao, Dr. Sun and Ms. Cheng that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to Dr. Sun and Ms. Cheng.

CHANGE IN MEMBER OF THE REMUNERATION COMMITTEE

The Board further announces that Mr. Lang Xiaofeng (“**Mr. Lang**”) has been appointed as a member of the Remuneration Committee with effect from 22 September 2026.

Following the resignation of Mr. Pu and the appointment of Mr. Lang, the Remuneration Committee comprises three members, namely Mr. Lang Xiaofeng, Mr. Dang Jinxue and Mr. Zhou Xiangliang.

APPOINTMENT OF MEMBER OF THE AUDIT COMMITTEE AND THE NOMINATION COMMITTEE

The Board further announces that Dr. Sun has been appointed as a member of the audit committee of the Board (“**Audit Committee**”) and Ms. Cheng has been appointed as a member of the Nomination Committee with effect from 22 September 2026.

RE-COMPLIANCE WITH RULES 3.10(1), 3.10A, 3.21 AND 3.27A OF THE LISTING RULES

Following the resignation of Mr. Pu Chengchuan as an executive Director and the appointment of Ms. Cheng Jessica as an independent non-executive Director and as a member of the Nomination Committee, the appointment of Dr. Sun Changyu as a non-executive Director and as a member of the Audit Committee, the number of independent non-executive Directors and the composition of the Board, the Audit Committee and the Nomination Committee are now in compliance with the requirements set out in Rules 3.10(1), 3.10A, 3.21 and 3.27A of the Listing Rules:

- (i) the Board comprises three independent non-executive Directors, meeting the minimum number required under Rule 3.10(1) of the Listing Rules;
- (ii) the three independent non-executive Directors represent at least one-third of the members of the Board, meeting the requirement under Rule 3.10A of the Listing Rules;
- (iii) the Audit Committee comprises three members, meeting the minimum number required under Rule 3.21 of the Listing Rules; and
- (iv) the Nomination Committee comprises five members, three of whom are independent non-executive Directors, meeting the requirement for a majority of independent non-executive Directors under Rule 3.27A of the Listing Rules.

Accordingly, the Company has re-complied with Rules 3.10(1), 3.10A, 3.21 and 3.27A of the Listing Rules.

By Order of the Board
Hospital Corporation of China Limited
Cao Yonggang
Chairman

Hong Kong, 22 September 2026

As at the date of this announcement, the Directors of the Company are Mr. Cao Yonggang, Mr. Lang Xiaofeng and Ms. Pan Jianli being the executive Directors; Dr. Sun Changyu, Ms. Liu Lu and Ms. Wang Nan being the non-executive Directors; Mr. Dang Jinxue, Ms. Cheng Jessica and Mr. Zhou Xiangliang being the independent non-executive Directors.